Overall survival of patients with metastatic KRAS wild type colorectal cancer patients treated with anti-EGFR third line monotherapy

Introduction. There is no evidence-based data comparing upfront chemotherapy doublets with anti-EGFR monoclonal antibody with sequential treatment utilizing anti-EGFR monotherapy as a consecutive line of treatment in patients with metastatic colorectal cancer. Here we report real-world survival data for patients with colorectal cancer (CRC) treated with anti-EGFR monoclonal antibody as 3rd line monotherapy.Material and methods. It was single center retrospective study. We collected retrospectively data of wild-type KRAS metastatic CRC patients who have failed oxaliplatin-and irinotecan based therapy and were treated with anti-EGFR monoclonal antibody as the 3. line monotherapy in 2009-2017 in Copernicus Memorial Hospital, Lodz, Poland. Last observation was recorded in February 2020. We calculated median overall survival (since commence-ment of palliative systemic treatment), median progression free survival and median OSIII (overall survival sine commencement of monotherapy with anti-EGFR agent).Results. 130 patients were included in the study. 40.6% were females. The median age was 63 years (range 38-83). 57% of patients were initially diagnosed with metastatic/inoperable colorectal cancer. 80 patients were treated with 3. line cetuximab, 50 - with panitumumab. At the moment of data analysis 123 deaths were recorded. OS since start of palliative systemic treatment was calculated for 120 patients and its median was 25.8 months. MPFS since start of anti-EGFR antibody was 4.3 months, mOSIII -10.7 months.Conclusions. 3rd line treatment of metastatic colorectal cancer with anti-EGFR antibodies is effective. It is good option for patients, who are not fit enough or not willing to have 1st line triplet therapy.